New eye drug challenges standard treatment for Diabetes-Related vision loss

This study tested whether a drug called PRO-169 works as well as the standard treatment, Lucentis (ranibizumab), for diabetic macular edema—a common cause of vision loss in people with diabetes. Over 500 adults received monthly eye injections of one of the two drugs for a year, with doctors tracking changes in their vision and eye health. The goal was to see if PRO-169 could control the swelling in the retina and improve vision just as effectively as the established treatment.